2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Karen A. Hicks(Moffitt Cancer Center), Robert J. Temple(Center for Drug Evaluation and Research), Hylton V. Joffe(Center for Drug Evaluation and Research), Shari Targum(Center for Drug Evaluation and Research), Roxana Mehran(Mount Sinai Hospital), John R. Teerlink(University of Glasgow), Billy Dunn(Center for Drug Evaluation and Research), Andrew Farb(Memorial Hermann), Eldrin F. Lewis(Brigham and Women's Hospital), Mary Thanh Hai(Center for Drug Evaluation and Research), John J.V. McMurray(University of Glasgow), Kenneth Rosenfield(Massachusetts General Hospital), Marc A. Pfeffer(Brigham and Women's Hospital), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Paul Burton(Newcastle University), Alexandra J. Lansky(Queen Mary University of London), Steven E. Nissen(Cleveland Clinic), Hung Hung(Center for Drug Evaluation and Research), Steven R. Steinhubl(Purdue University West Lafayette), Scott D. Solomon(Brigham and Women's Hospital), Donald E. Cutlip(Baim Institute for Clinical Research), David A. Morrow(University of California, San Francisco), Michael R. Jaff(Boston Scientific (United States)), Steven S. Brooks(Data Voice Exchange (United States)), Bernard Chaitman(Saint Louis University), Martin Landray(Gentofte Hospital), Laura Mauri(Brigham and Women's Hospital), James E. Tcheng(Duke University), Akshay S. Desai(Brigham and Women's Hospital), Christopher J. White(Ochsner Medical Center), Cathy Sila(University Hospitals of Cleveland), John R. Marler(Center for Drug Evaluation and Research), Stephen D. Wiviott(Brigham and Women's Hospital), Michaël Domanski(Mount Sinai Hospital), Christopher M. O’Connor(Inova Health System), A. Michael Lincoff(Cleveland Clinic), Norman Stockbridge(United States Food and Drug Administration), C. Michael Gibson(Baim Institute for Clinical Research)
Circulation
February 26, 2018
Cited by 712


Related Papers